Truist Financial Forecasts Strong Price Appreciation for Biogen (NASDAQ:BIIB) Stock

Biogen (NASDAQ:BIIB) had its target price hoisted by stock analysts at Truist Financial from $190.00 to $193.00 in a research report issued to clients and investors on Monday, Marketbeat.com reports. The firm presently has a “hold” rating on the biotechnology company’s stock. Truist Financial’s target price would indicate a potential downside of 4.07% from the stock’s current price.

Several other brokerages have also recently issued reports on BIIB. Piper Sandler lifted their price objective on shares of Biogen from $157.00 to $177.00 and gave the stock a “neutral” rating in a research note on Monday. Wall Street Zen cut Biogen from a “buy” rating to a “hold” rating in a report on Sunday, November 9th. Guggenheim reiterated a “buy” rating and set a $246.00 price objective on shares of Biogen in a research report on Monday. TD Cowen restated a “buy” rating on shares of Biogen in a report on Monday. Finally, Wells Fargo & Company set a $200.00 target price on Biogen in a report on Sunday. Thirteen analysts have rated the stock with a Buy rating and fifteen have assigned a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $202.50.

Biogen Stock Up 8.5%

Shares of NASDAQ:BIIB opened at $201.18 on Monday. The firm has a market cap of $29.51 billion, a PE ratio of 22.84, a price-to-earnings-growth ratio of 1.70 and a beta of 0.16. The company has a fifty day simple moving average of $176.94 and a 200 day simple moving average of $157.05. The company has a current ratio of 2.68, a quick ratio of 2.03 and a debt-to-equity ratio of 0.34. Biogen has a 12-month low of $110.04 and a 12-month high of $202.41.

Biogen (NASDAQ:BIIB) last released its quarterly earnings data on Friday, February 6th. The biotechnology company reported $1.99 EPS for the quarter, topping analysts’ consensus estimates of $1.61 by $0.38. Biogen had a net margin of 13.07% and a return on equity of 12.64%. The firm had revenue of $2.28 billion during the quarter, compared to the consensus estimate of $2.21 billion. During the same quarter in the previous year, the company posted $3.44 earnings per share. The firm’s revenue was down 7.2% on a year-over-year basis. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. On average, equities research analysts anticipate that Biogen will post 15.83 EPS for the current fiscal year.

Insider Transactions at Biogen

In other news, insider Priya Singhal sold 748 shares of Biogen stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $179.30, for a total transaction of $134,116.40. Following the sale, the insider directly owned 6,271 shares in the company, valued at approximately $1,124,390.30. The trade was a 10.66% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.18% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Biogen

Several large investors have recently modified their holdings of the business. Advisory Services Network LLC lifted its stake in Biogen by 3.9% in the 3rd quarter. Advisory Services Network LLC now owns 1,792 shares of the biotechnology company’s stock valued at $251,000 after acquiring an additional 68 shares in the last quarter. CVA Family Office LLC lifted its position in shares of Biogen by 18.1% in the third quarter. CVA Family Office LLC now owns 464 shares of the biotechnology company’s stock worth $65,000 after purchasing an additional 71 shares in the last quarter. Davis Investment Partners LLC boosted its holdings in Biogen by 1.7% during the fourth quarter. Davis Investment Partners LLC now owns 4,374 shares of the biotechnology company’s stock worth $778,000 after purchasing an additional 71 shares during the last quarter. Optas LLC grew its position in Biogen by 4.5% in the fourth quarter. Optas LLC now owns 1,706 shares of the biotechnology company’s stock valued at $300,000 after purchasing an additional 73 shares in the last quarter. Finally, TD Private Client Wealth LLC increased its stake in Biogen by 22.5% in the 3rd quarter. TD Private Client Wealth LLC now owns 414 shares of the biotechnology company’s stock valued at $58,000 after buying an additional 76 shares during the last quarter. 87.93% of the stock is currently owned by institutional investors.

Key Stories Impacting Biogen

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Multiple firms raised price targets and reiterated buy views — HC Wainwright lifted its PT to $228 and Stifel moved to $214 (both buy). These upgrades support upside expectations for the stock.
• Positive Sentiment: Q4 results beat expectations: EPS $1.99 vs. $1.61 est., revenue topped estimates and management issued strong FY2026 EPS guidance (15.25–16.25), which underpins the rally. Biogen shares rise as Q4 earnings beat expectations, 2026 profit outlook strong
• Positive Sentiment: Commercial momentum for Leqembi is a key catalyst — sales jumped and market optimism rose after reports China fast‑tracked at‑home use of Leqembi, which could open a major market. Biogen stock to pop again? China fast-tracks at-home Alzheimer’s drug Leqembi
• Positive Sentiment: Shares recently hit a 52‑week high on the earnings/Leqembi news, reinforcing momentum and investor interest. Biogen Hits 52-Week High, Alzheimer’s Drug Sales Jump
• Neutral Sentiment: Analyst nuance: TD Cowen and others maintain bullish views citing undervaluation and growing Leqembi cash flows, but nuance remains around sustainability. Biogen: Undervalued Cash Flows and Growing Leqembi Franchise Support Raised Price Target and Buy Rating
• Neutral Sentiment: Deeper analysis: some coverage frames FY25 EPS as “stable” but notes pressure from the MS franchise — a balanced read for investors weighing sustainability. Biogen FY25 Earnings: Stable EPS, Amid Pressure From The Multiple Sclerosis Franchise
• Negative Sentiment: MS franchise weakness: core MS sales declined, which weighed on top‑line growth and is flagged as a recurring headwind by some outlets. Biogen Revenue Down as Multiple Sclerosis Sales Slide
• Negative Sentiment: Some major sell‑side analysts (Morgan Stanley, UBS) remain at Hold with lower PTs (~$185–$190), citing limited near‑term growth and pipeline/execution risk — these views cap upside for more cautious investors. Biogen: Limited Near-Term Growth and Execution Risks Justify Neutral Hold Rating Biogen: Solid Near-Term Execution but High-Risk Pipeline Keeps Rating at Hold

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.